Pennytobuck.coms Stock Report On Pwrm, Forr, Siga, Sppi
POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
Last: $0.036
PWRM is still available for $0.036 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets
The intellectual property that PWRM has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:
Continue your research at www.power3medical.com
American Express, CDW, and Dell are the winners of the 2010 Forrester Research (Nasdaq: FORR) Voice Of The Customer Awards, announced at Forrester"s Customer Experience Forum 2010. The Voice Of The Customer Awards recognize initiatives that enable companies to dramatically improve how they collect, interpret, and react to customer feedback. Close to 900 people attended the New York event, which was targeted at Customer Experience professionals.
"The quality of this year"s nominees is evidence that voice of the customer programs are advancing rapidly," said Harley Manning, vice president, research director, Forrester Research. "The best VoC programs demonstrate that executive involvement, measurement, and insights that are tied directly to action are critical to customer experience success."
Forrester Research, Inc. (Nasdaq: FORR) is an independent research company that provides pragmatic and forward-thinking advice to global leaders in business and technology. Forrester works with professionals in 19 key roles at major companies providing proprietary research, customer insight, consulting, events, and peer-to-peer executive programs. For more than 26 years, Forrester has been making IT, marketing, and technology industry leaders successful every day. For more information, visit www.forrester.com.
SIGA Technologies, Inc.
(Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246(R), SIGA"s lead smallpox antiviral drug candidate. Analyses of the trial"s results are consistent with findings from previous studies of ST-246 and together show that the drug will likely be found to be a safe and well-tolerated therapeutic for the treatment of orthopoxvirus infections.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA"s web site at http://www.siga.com/.
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology and hematology, announced that it has appointed James E. Shields, a seasoned pharmaceutical sales executive with a proven track record of establishing and leading commercial operations, to the position of Senior Vice President and Chief Commercial Officer. Mr. Shields" appointment is an important component of the Company"s continued focus on maximizing the growth potential of its ZEVALIN and FUSILEV brands, and as it makes launch preparations for its other late-stage drugs in the near future.
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology and hematology. The Company"s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to continuing to build an efficient in-house clinical research organization with regulatory and data management capabilities, the Company has established a commercial infrastructure to market its drug portfolio. The Company markets two oncology drugs, ZEVALIN and FUSILEV, and has two drugs in late stage development, apaziquone and belinostat, along with a diverse pipeline. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company"s website at www.sppirx.com.
***********************************
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
***********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
by: Bill Pennyman
The Pros and Cons of a No Annual Fee Card The Inshore Model That Can Transform your Enterprise into an Agile and Competitive Entity What Are Twist Ties and How Are They More Useful Than Other Kinds of Ties Adhering to Surviving Earthquakes and Air Raids The Land Of The Rising Sun: Where Incredible Natural Landscapes And Bustling City Life Collide What Are Cable Ties and Why Are They So Important? Significant Things To Know About Va's Aid And Attendance Benefit Make Them Save Some and You too Make Something Ignore Hepatitis Testing And You Are Headed Towards Long Term Illness!! Rugged Ridge Bumpers: Uses And Highlights Drake Tickets - Selling Tunes And Blackberries Muse Tickets - Taking On 'voodoo' And Vampires What Is A Pain Clinic And How Can It Help You?